HPE CINV Pocket Guide 2018 | Page 48

figure 1 Economic evaluation of healthcare programmes Are both costs and consequences of the No Examines only Examines only consequences costs Is there Partial evaluation No comparison of Outcome Cost description two or more description Partial evaluation alternatives? Yes Efficacy or Cost analysis effectiveness evaluation Adapted from reference 12 treatments are compared only on the basis of costs). For instance, a cost-analysis study 14 conducted when 5-HT 3 receptor antagonists were introduced showed that the introduction of such therapy entailed an increase of 3–10% of total costs compared with standard antiemetic treatments at the time. Full economic evaluations are those studies where two or more treatments are compared on the basis of both clinical consequences and costs. 14 They can be cost-minimisation analyses (where the incremental effectiveness of one health programme or technology compared 48 | 2018 | hospitalpharmacyeurope. com to the other is the same), cost- effectiveness analyses (measuring incremental cost of achieving an incremental health benefit, such as life-years gained), cost–utility analyses (where effectiveness is adjusted for quality of life), or cost–benefit analyses (where both incremental costs and outcomes are valued in monetary terms). When considering the adoption of a therapy to prevent or treat CINV episodes over an existing practice, the additional benefits provided by the drug (improved outcomes) need to be weighed against its incremental cost (Figure 1). This